Thermo Fisher Scientific CIP2A Monoclonal Antibody (2A1-9A4)

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Immunoprecipitation (IP)

Assay-dependent

-

Product Specifications

Species Reactivity

Human, Mouse

Host/Isotype

Mouse / IgG1, kappa

Class

Monoclonal

Type

Antibody

Clone

2A1-9A4

Immunogen

The amino terminal one-third of the CIP2A Recombinant protein. if (typeof window.$mangular === undefined || !window.$mangular) { window.$mangular = {}; } $mangular.antigenJson = \[{targetFamily:CIP2A,uniProtId:Q8TCG1-1,ncbiNodeId:9606,antigenRange:1,antigenLength:905,antigenImageFileName:A500-010ACF_CIP2A_Q8TCG1-1_House_mouse.svg,antigenImageFileNamePDP:A500-010ACF_CIP2A_Q8TCG1-1_House_mouse_PDP.jpeg,sortOrder:1}\]; $mangular.isB2BCMGT = false; $mangular.isEpitopesModalImageMultiSizeEnabled = true;

View immunogen .st0{fill:#FFFFFF;} .st1{fill:#1E8AE7;}

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

purified

Storage buffer

TBS, pH 6.8 to 7.4

Contains

0.09% sodium azide

Storage conditions

4° C

Shipping conditions

Ambient (domestic); Wet ice (international)

Target Information

Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. The protein, designated Cancerous Inhibitor of PP2A (CIP2A), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.